Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Nykode Therapeutics ASA banner
N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 3.74 NOK 2.97% Market Closed
Market Cap: kr1.2B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 2.24 NOK with a low forecast of 2.22 NOK and a high forecast of 2.31 NOK.

NYKD Lowest Forecast
Wall Street Target
2.22 NOK
-41% Downside
NYKD Average Forecast
Wall Street Target
2.24 NOK
-40% Downside
NYKD Highest Forecast
Wall Street Target
2.31 NOK
-38% Downside
Lowest
Price Target
2.22 NOK
41% Downside
Average
Price Target
2.24 NOK
40% Downside
Highest
Price Target
2.31 NOK
38% Downside
Nykode Therapeutics ASA Competitors:
Price Targets
IDXX
IDEXX Laboratories Inc
21% Upside
FLEX
Flex Ltd
18% Upside
INO
Inovio Pharmaceuticals Inc
417% Upside
IDXX
IDEXX Laboratories Inc
21% Upside
FLEX
Flex Ltd
18% Upside
INO
Inovio Pharmaceuticals Inc
417% Upside

Revenue
Forecast

110% / Year
Past Growth
-46% / Year
Estimated Growth
Estimates Accuracy
N/A
Average
110% / Year
Past Growth
-46% / Year
Estimated Growth
Estimates Accuracy
N/A
Average

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -46%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

What are analyst estimates?

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
2.24 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 2.24 NOK with a low forecast of 2.22 NOK and a high forecast of 2.31 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-46%

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -46%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.